Callan Family Office LLC Purchases 9,079 Shares of GSK PLC Sponsored ADR (NYSE:GSK)

Key Points

• Callan Family Office LLC has increased its holdings in GSK PLC Sponsored ADR by 15.7%, purchasing an additional 9,079 shares, bringing its total ownership to 66,791 shares valued at approximately $2.59 million.
• GSK reported earnings of $1.23 per share for the last quarter, exceeding analysts' expectations and showing a 1.3% year-over-year revenue increase.
• The company has announced a quarterly dividend of $0.4206 per share, translating to an annualized dividend of $1.68 and a yield of 4.5%.

Callan Family Office LLC lifted its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 15.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,791 shares of the pharmaceutical company's stock after buying an additional 9,079 shares during the quarter. Callan Family Office LLC's holdings in GSK were worth $2,587,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Kingsview Wealth Management LLC grew its position in shares of GSK by 1.8% during the 1st quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company's stock worth $590,000 after buying an additional 271 shares during the period. Rehmann Capital Advisory Group grew its position in shares of GSK by 4.6% during the 1st quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company's stock worth $248,000 after buying an additional 279 shares during the period. First PREMIER Bank grew its position in shares of GSK by 6.5% during the 1st quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company's stock worth $181,000 after buying an additional 286 shares during the period. Northwest Bank & Trust Co grew its position in shares of GSK by 1.3% during the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock worth $765,000 after buying an additional 289 shares during the period. Finally, OneAscent Financial Services LLC boosted its stake in GSK by 3.9% during the 1st quarter. OneAscent Financial Services LLC now owns 7,700 shares of the pharmaceutical company's stock worth $297,000 after acquiring an additional 292 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Stock Up 0.2%

GSK traded up $0.07 during trading on Friday, reaching $39.30. The company had a trading volume of 3,038,539 shares, compared to its average volume of 4,741,255. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. GSK PLC Sponsored ADR has a 12 month low of $31.72 and a 12 month high of $44.67. The business's fifty day moving average price is $38.50 and its 200 day moving average price is $37.95. The company has a market cap of $80.14 billion, a P/E ratio of 18.19, a PEG ratio of 1.71 and a beta of 0.51.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%. The firm had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. During the same quarter last year, the business posted $0.43 EPS. The company's revenue for the quarter was up 1.3% on a year-over-year basis. Equities analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be paid a $0.4206 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.3%. GSK's dividend payout ratio (DPR) is currently 77.78%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GSK. Wall Street Zen raised shares of GSK from a "hold" rating to a "buy" rating in a research note on Sunday, August 3rd. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Finally, Berenberg Bank reissued a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.